Area of research
Hematology · Public Health, Environmental and Occupational Health
Research interest
Research interests include Acute Myeloid Leukemia Research, Acute Lymphoblastic Leukemia research, Retinoids in leukemia and cellular processes, and Chronic Myeloid Leukemia Treatments.
Acute myeloid leukaemia cells express high levels of androgen receptor but do not depend on androgen signaling for survival.
Postinduction molecular MRD identifies patients with <i>NPM1</i> AML who benefit from allogeneic transplant in first remission
Unified classification and risk-stratification in Acute Myeloid Leukemia
Unified classification and risk-stratification in Acute Myeloid Leukemia.
Author Correction: Genome-wide association study identifies susceptibility loci for acute myeloid leukemia.
Genome-wide association study identifies susceptibility loci for acute myeloid leukemia
Characteristics and outcome of patients with acute myeloid leukaemia and t(8;16)(p11;p13): results from an International Collaborative Study*
Genome-wide association study identifies susceptibility loci for acute myeloid leukemia.
Molecular MRD status and outcome after transplantation in NPM1-mutated AML
AML: New Drugs but New Challenges
Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet
Allogeneic hematopoietic cell transplantation improves outcome of adults with t(6;9) acute myeloid leukemia: results from an international collaborative study
Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial
Characteristics and outcome of patients with therapy-related acute promyelocytic leukemia front-line treated with or without arsenic trioxide
Assessment of Minimal Residual Disease in Standard-Risk AML
Expression of CD33 is a predictive factor for effect of gemtuzumab ozogamicin at different doses in adult acute myeloid leukaemia
Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial
A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients
Downregulation of the Wnt inhibitor CXXC5 predicts a better prognosis in acute myeloid leukemia
Hyperdiploidy with 49–65 chromosomes represents a heterogeneous cytogenetic subgroup of acute myeloid leukemia with differential outcome
Final Results of a Phase 2 Open-Label, Monotherapy Efficacy and Safety Study of Quizartinib (AC220) in Patients with FLT3-ITD Positive or Negative Relapsed/Refractory Acute Myeloid Leukemia After Second-Line Chemotherapy or Hematopoietic Stem Cell Transplantation
Azacitidine fails to eradicate leukemic stem/progenitor cell populations in patients with acute myeloid leukemia and myelodysplasia
Final Results of a Phase 2 Open-Label, Monotherapy Efficacy and Safety Study of Quizartinib (AC220) in Patients ≥ 60 Years of Age with FLT3 ITD Positive or Negative Relapsed/Refractory Acute Myeloid Leukemia
Gemtuzumab Ozogamicin: Time to Resurrect?